RAD 602
Alternative Names: Lu177-labelled radiopharmaceutical theranostic; PTPµ-targeted theranostic; RAD-602Latest Information Update: 28 Jul 2026
At a glance
- Originator Case Western Reserve University School of Medicine
- Developer Radiopharm Theranostics
- Class Antineoplastics; Imaging agents; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Glioblastoma in Australia (Parenteral)
- 28 Jul 2026 No recent reports of development identified for preclinical development in Glioblastoma(Diagnosis) in Australia (Parenteral)
- 17 Apr 2023 Radiopharm Theranostics enters into supply agreement with TerThera for Terbium-161 isotope to develop RAD 602